Candel Therapeutics CEO Paul FMedSci's 2021 pay falls 64% to $957K
Candel Therapeutics reports 2021 executive compensation
By ExecPay News
Published: September 2, 2022
Candel Therapeutics reported fiscal year 2021 executive compensation information on September 2, 2022.
In 2021, four executives at Candel Therapeutics received on average a compensation package of $574K, a 63% decrease compared to previous year.
Average pay of disclosed executives at Candel Therapeutics
Paul Peter Tak, M.D., Ph.D., FMedSci, Chief Executive Officer, received $957K in total, which decreased by 64% compared to 2020. 57% of FMedSci's compensation, or $545K, was in salary. FMedSci also received $85K in bonus, $168K in non-equity incentive plan, as well as $159K in other compensation.
Estuardo Aguilar-Cordova, M.D., inf., Chief Executive Officer, received a compensation package of $526K, which decreased by 29% compared to previous year. 99% of the compensation package, or $520K, was in salary.
John Canepa, Chief Financial Officer, earned $449K in 2021, a 66% decrease compared to previous year.
Francesca Barone, Chief Scientific Officer, received $365K in 2021.
Related executives
You may also like
Source: SEC filing on September 2, 2022.